Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting (GlobeNewswire) - Oct 27, 2021 - P1/2, N=55; ReSPECT (NCT01906385); Sponsor: Plus Therapeutics; "Data from the ePoster...demonstrated the following: (i) Mean locoregional retention in the brain volume at the end of infusion (85.9% ± 17.1% ID, n=18) and at eight days post-infusion (46.6% ± 16.7% ID, n=17); (ii) Following dose escalation, the mean radiation absorbed dose in the two most recent cohorts to the tumor volume was 354.7 ± 144.0 Gy, to the whole brain was 1.32 ± 1.06 Gy, and to the whole body was 0.16 ± 0.04 Gy (n=6), establishing evidence of a high radiation absorbed dose to the tumor with minimal brain and whole body radiation exposure."
P1/2 data • CNS Tumor • Glioblastoma • Glioma • Oncology
|